(NRIX) Nurix Therapeutics - Ratings and Ratios
Cancer, Autoimmune, Inflammatory, Therapies, BTK, Inhibitors, Partnerships
NRIX EPS (Earnings per Share)
NRIX Revenue
Description: NRIX Nurix Therapeutics
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is revolutionizing the treatment of cancer, inflammatory conditions, and other diseases through its innovative small molecule and antibody therapies. With a robust pipeline of promising candidates, the company is poised to make a significant impact in the biotech industry.
The companys lead candidates, including NX-5948, NX-2127, and NX-1607, are demonstrating potential in treating various diseases, from relapsed or refractory B-cell malignancies to autoimmune diseases and immuno-oncology indications. NX-5948, an orally bioavailable BTK degrader, is in Phase 1B/2 clinical trials, while NX-2127, another BTK degrader, is in Phase 1A clinical trials. Meanwhile, NX-1607, a CBL-B inhibitor, is also in Phase 1A clinical trials, targeting immuno-oncology indications.
Nurix Therapeutics has established strategic collaborations with industry giants Gilead Sciences, Sanofi, and Pfizer, which will aid in the co-development and co-commercialization of multiple drug candidates. This collaboration will not only accelerate the development of Nurixs pipeline but also provide the company with significant financial and operational support.
Analyzing the
Forecasting the stocks performance, we can expect NRIX to continue its upward trend if it can break through the $17.77 resistance level. With a robust pipeline and strategic collaborations, the company is well-positioned for long-term growth. However, investors should be cautious of the high volatility, as indicated by the ATR of 0.66, which translates to a 5.76% daily price movement. A potential entry point could be around $10.50, with a stop-loss at $9.50. A successful breakout above $17.77 could see the stock targeting $25-$30 in the short term.
Additional Sources for NRIX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
NRIX Stock Overview
Market Cap in USD | 970m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-07-24 |
NRIX Stock Ratings
Growth Rating | -49.4 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -34.5 |
Analysts | 4.44 of 5 |
Fair Price Momentum | 10.63 USD |
Fair Price DCF | - |
NRIX Dividends
Currently no dividends paidNRIX Growth Ratios
Growth Correlation 3m | 66.8% |
Growth Correlation 12m | -85.2% |
Growth Correlation 5y | -53.5% |
CAGR 5y | -8.55% |
CAGR/Max DD 5y | -0.09 |
Sharpe Ratio 12m | -1.07 |
Alpha | -61.33 |
Beta | 1.873 |
Volatility | 62.67% |
Current Volume | 565.3k |
Average Volume 20d | 609.6k |
Stop Loss | 11.4 (-6.6%) |
As of July 09, 2025, the stock is trading at USD 12.21 with a total of 565,267 shares traded.
Over the past week, the price has changed by +4.27%, over one month by -2.63%, over three months by +31.86% and over the past year by -40.44%.
Probably not. Based on ValueRay´s Analyses, Nurix Therapeutics (NASDAQ:NRIX) is currently (July 2025) not a good stock to buy. It has a ValueRay Growth Rating of -49.40 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NRIX is around 10.63 USD . This means that NRIX is currently overvalued and has a potential downside of -12.94%.
Nurix Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy NRIX.
- Strong Buy: 10
- Buy: 6
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, NRIX Nurix Therapeutics will be worth about 12.8 in July 2026. The stock is currently trading at 12.21. This means that the stock has a potential upside of +4.5%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 30.3 | 148.4% |
Analysts Target Price | 30.3 | 148% |
ValueRay Target Price | 12.8 | 4.5% |